NCT07029243 Prehab and Creatine/Whey Supplementation in Frailty Among Patients With Cirrhosis
| NCT ID | NCT07029243 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, San Francisco |
| Condition | Cirrhosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-04-15 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2026-04-15 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Frailty and muscle health are important for patients with chronic liver disease. This study looks at the use of a digital prehabilitation app (HEAL-ME) plus creatine and whey protein combination supplementation on maintaining muscle health in patients with liver disease. The investigators anticipate that this combination of supplementation and nutrition/exercise prehabilitation app will maintain muscle health in patients with liver disease.
Eligibility Criteria
Inclusion Criteria: * Confirmed diagnosis of cirrhosis by ICD-10 code, liver biopsy, abdominal imaging, or transient elastography * Access to digital device and internet at home * Ability to provide written informed consent before any study-related activities * Ability to remain in study for at least 3 months Exclusion Criteria: * Allergy to milk protein * On hemodialysis * No English language proficiency * Presence of condition or abnormality that in opinion of the Investigator will compromise safety of the patient or quality of the data * Concomitant severe underlying systemic illness that in the opinion of the Investigator would interfere with completion of study * Pregnant, breastfeeding, or intention of becoming pregnant during study time frame
Contact & Investigator
Jennifer Lai, MD, MBA
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT07029243 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cirrhosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07029243 currently recruiting?
Yes, NCT07029243 is actively recruiting participants. Contact the research team at melinda.wang3@ucsf.edu for enrollment information.
Where is the NCT07029243 trial being conducted?
This trial is being conducted at San Francisco, United States.
Who is sponsoring the NCT07029243 clinical trial?
NCT07029243 is sponsored by University of California, San Francisco. The principal investigator is Jennifer Lai, MD, MBA at University of California, San Francisco. The trial plans to enroll 100 participants.